Pharmacotherapy & Evidence-Based Treatment:
Comprehensive Overview of Clinical Cessation Protocols (LMIC vs HIC)

"Tobacco dependence remains the leading single cause of preventable global morbidity and mortality, accounting for over 7 million deaths annually among 1.3 billion tobacco users worldwide. An acute global equity gap persists: 80% of all tobacco users reside in Low- and Middle-Income Countries (LMICs), yet population-level access to World Health Organization (WHO) best-practice cessation services stands at only 4% in low-income countries and 11% in middle-income countries, compared to 28% in high- income countries (HICs). While HIC treatment guidelines rely heavily on insurance-covered, high-cost first-line pharmacotherapies such as Varenicline ($400–$500 per course) and combination nicotine replacement therapy (NRT), LMIC populations face a severe economic hurdle where the out-of-pocket cost for a single month of NRT frequently exceeds the cost of continuing to smoke. This presentation evaluates strategies to bridge this global divide by analyzing the neurobiological imperatives of tobacco addiction, comparing clinical treatment guidelines, and introducing high-efficacy, low-cost pharmacotherapy combined with scalable community delivery models. Neurobiological evidence confirms that tobacco dependence is a physiological receptor-driven addiction requiring pharmacotherapy, which quintuples cessation success compared to unassisted quit attempts (~25% vs ~5%). Cytisine—a plant-based partial α4β2 nicotinic receptor agonist costing ~$20–$30 per treatment course—emerges as a transformative solution for LMICs. Clinical evidence from the randomized, double-blind Thai STEP trial (Respirology 2024; n=1,086) demonstrated that a 25-day course of locally manufactured Cytisine achieved non-inferior continuous abstinence rates compared to a 12-week course of Nortriptyline (10% at 12 months) with favorable tolerability. To operationalize these findings in resource-constrained health systems, a three-tiered LMIC master-algorithm is presented: task-shifting initial screening (Ask & Advise) to Community Health Workers, scaling automated mobile mCessation behavioral support, and providing generic Cytisine. Because global tobacco control 's primary challenge is structural rather than scientific, pairing affordable essential medicines with community-based participatory care offers a proven, equitable path toward reducing global tobacco mortality."